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Abstract: Diet is a key modifiable risk factor for non-communicable diseases. However, we currently
are not benefitting from the full potential of its protective effects. This is due to a number of reasons,
including high individual variability in response to certain diets. It is now well acknowledged that
in order to gain the full benefit of dietary regimes it is essential to take into account individual
responses. With this in mind, the present review examines the concept of precision nutrition and
the performance of n-of-1 studies, and discusses the development of certain approaches that will be
critical for development of the concepts.
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1. Diet, Dietary Efficacy, and Dietary Advice
Dietary risk factors are currently the most important risk factor for the Global Burden of
Disease—globally, in 2013, dietary risks accounted for 11.3 million deaths and 241.4 million
disability-adjusted life-years. Dietary risks include a diet low in vegetables, low in seafood, low in
whole grains, low in nuts/seeds, low in milk, and high in red meat [1]. Furthermore, nutritional
practices have been shown to reduce the risk of cardiovascular disease by 60% [2], and it is estimated
that 27–39% of the main cancers can be prevented by improving diet, physical activity, and body
composition [3]. The efficacy by which dietary interventions influence health is currently mainly
determined by taking population-based approaches that can favourably shift disease risk factors
in the entire population [4]. However, these approaches may be ineffective as two major issues
are overlooked.
First of all, although intuitively appealing to try and encourage healthy food choice through
information provision and education, knowledge alone is typically insufficient to change behaviour.
While the vast majority of people know what they ‘should’ and ‘should not’ eat, turning intentions
into action is notoriously difficult. Less than a quarter of all people who embark on a healthy eating
plan still stick to it 12 months later [5]. Laboratory studies demonstrate that self-control resources
are finite and people have a limited amount of the mental energy required to resist temptation [6].
In most European countries, eating styles do not match with basic recommendations. Despite some
improvements, diets still contain too much saturated fat, sugar, and salt, and insufficient vegetables,
fruits, and fish [7]. This is specifically problematic for those already suffering from diseases where diet
plays an important role in its aetiology, like metabolic diseases. Highly-perceived susceptibility to
disease is, however, known to influence motivation for individual behaviour change [8], and therefore,
diets tailored to individual circumstances may prove more effective.
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Secondly, it is now becoming clear that there is considerable inter-individual variation in response
to dietary interventions, and some interventions may benefit certain individuals or population
subgroups more than others, depending on their genotype, phenotype, and environment [9,10].
Many of the large, randomised controlled trials have effectively demonstrated that only 40% of
a cohort responds to the dietary interventions [11], and lifestyle measures that reduce disease risk
in an entire population may offer little benefit to a specific individual. This means that for the same
dietary intake, exposure to bioactive metabolites can markedly differ between individuals. For example,
the inter-individual variation in response to eating beneficial plant food bioactives may result from
a range of determinants including age, sex, habitual dietary habits, genetics, epigenetics, and gut
microbiota. This will affect the absorption, distribution, metabolism, and excretion of compounds
and metabolites, and thus affect biovailability and biological responsiveness [12]. For example,
‘responders’ and ‘non-responders’ to carotenoids, classified as subjects with high or low carotenoid
status upon consumption, respectively, may be explained by variants of genes encoding proteins
involved in the absorption and metabolism of carotenoids, such as SR-BI (scavenger receptor class B,
member 1) and CD36 (CD36 molecule, thrombospondin receptor), which are involved in the uptake
of carotenoids by intestinal cells, as well as BCO1 (beta-carotene oxygenase 1), which catalyses the
oxidative cleavage of carotenoids into vitamin A [13]. Gut microbiota are known to play an important
role in efficacy of the soy isoflavone diadzin/daidzein. This plant bioactive is converted into equol by
gut microbiota but only in 25–35% of the Western population and up to 50–70% of the vegetarian and
Asian populations [14,15]. In one of our recent controlled clinical trials we showed that consumption
of flavan-3-ol-enriched dark chocolate decreased platelet aggregation in males but not female subjects.
This effect could not be correlated with plasma or urine concentrations of flavan-3-ols metabolites,
suggesting that inter-individual variation in biological responses is not always due to variation in the
bioavailability of plant food bioactives but can depend on other factors also, such as sex [16].
2. Precision Medicine and Precision Nutrition
This phenomenon of inter-individual variability is not unique for nutrition sciences–medical
sciences have pioneered the introduction of Precision Medicine in an attempt to overcome and indeed
benefit from individualised/variable response to therapies. Recently, there has been significant
acceptance of the fact that the medical field needs to take individual variability into account, and indeed,
there has been a recent call for the development of n-of-1 clinical trials that focus on the individual,
and not average responses to medical therapy [17–19]. Furthermore, regulatory agencies such as the
US Food and Drug Administration (FDA) are also recognising the importance of individual responses.
These so called n-of-1 trials focus on a single person with data collected over a time-course as the
individual undergoes different treatments (see Figure 1). Aggregated results of many n-of-1 trials
offer data on how to better treat sub-populations that share genetic and phenotypic factors, amongst
others, or the population at large [20,21]. Such trials can also employ omics-based technologies and
bioinformatics, so as to analyse and link the dynamics of thousands of molecules and parameters in
a single individual, and understand the differences of these dynamics between different individuals
and subgroups, providing a deeper understanding of dynamic changes in molecular components
and biological pathways across different health conditions and individuals. Indeed, monitoring
of the omics profiles of an individual has already been shown to be a useful tool in the dynamic
assessment of the physiology and health of an individual [22–24]. This approach has been coined as
iPOP (integrative personal omic profiling) and is set to identify new pathways and genes that are
related to disease development.
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Figure 1. Concept of n-of-1 trials leading to personalised interventions. 
In the field of personalised nutrition there have been a number of studies that have 
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a strategy for the prediction of glycemic responses to meals. To achieve this they monitored the 
responses to almost 47,000 meals which demonstrated a high variability in responses to identical 
meals. A machine-learning algorithm was applied to integrate dietary habits, anthropometric 
outcomes, physiological parameters in blood, levels of physical activity, and gut microbiota in order 
to develop a prediction model for the glycaemic response to real life meals. This prediction model 
was subsequently tested in an independent cohort of 100 persons. Finally, a randomised, controlled 
dietary intervention in 26 participants showed that the algorithm rightly predicted significantly 
lower postprandial responses for specific meals [9]. In a pan-European Study the Food4Me 
personalised intervention demonstrated that tailoring dietary advice to an individual level resulted 
in an improvement in the dietary quality of the participants, providing evidence for the efficacy of 
the approach [25]. A recent review further highlighted the emerging field of n-of-1 studies for 
precision nutrition [26]. 
3. Adaptation of Precision Nutrition Approaches in Future Studies 
The application of precision nutrition approaches has the potential to significantly affect the way 
we perform dietary intervention studies in the future. In addition, improved knowledge of individual 
factors that determine the bioavailability and efficacy of food components could improve the way we 
formulate dietary advice. Indeed, in the future this may lead to personalised and tailored dietary 
advice for individuals or population subgroups for foods or food groups. However, in order to make 
that transition from population-based guidelines to individual dietary advice, we will require the 
execution of many more carefully designed precision nutrition trials. Other factors that will 
determine the success of the implementation of precision nutrition approaches in future studies 
include the expansion of the field of metabolomics to allow deep phenotyping of baseline status and 
responses to dietary inventions, and an in-depth understanding of the role of nutrigenetics in the 
inter-individual responses to food components and products. More recently, evidence is beginning 
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In the field of personalised nutrition there have been a number of studies that have demonstrated
the potential of tailoring dietary advice to the individual level. Combining continuous monitoring of
glucose and omics techniques in an 800-person cohort, Zeevi and colleagues developed a strategy for
the prediction of glycemic responses to meals. To achieve this they monitored the responses to almost
47,000 meals which demonstrated a high variability in responses to identical meals. A machine-learning
algorithm was applied to integrate dietary habits, anthropometric outcomes, physiological parameters
in blood, levels of physical activity, and gut microbiota in order to develop a prediction model for the
glycaemic response to real life meals. This prediction model was subsequently tested in an independent
cohort of 100 persons. Finally, a randomised, controlled dietary intervention in 26 participants showed
that the algorithm rightly predicted significantly lower postprandial responses for specific meals [9].
In a pan-European Study the Food4Me personalised intervention demonstrated that tailoring dietary
advice to an individual level resulted in an improvement in the dietary quality of the participants,
providing evidence for the efficacy of the approach [25]. A recent review further highlighted the
emerging field of n-of-1 studies for precision nutrition [26].
3. Adaptation of Precision Nutrition Approaches in Future Studies
The application of precision nutrition approaches has the potential to significantly affect the way
we perform dietary intervention studies in the future. In addition, improved knowledge of individual
factors that determine the bioavailability and efficacy of food co ponents could improve the way
we formulate dietary advice. Indeed, in the future this may lead to personalised and tailored dietary
advice for individuals or population subgroups for foods or food groups. However, in order to make
that transition from population-based guidelines to individual dietary advice, we will require the
execution of many more carefully designed precision nutrition trials. Other factors that will determine
the success of the implementation of precision nutrition approaches in future studies include the
expansion of the field of metabolomics to allow deep phenotyping of baseline status and responses to
dietary inventions, and an in-depth understanding of the role of nutrigenetics in the inter-individual
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responses to food components and products. More recently, evidence is beginning to emerge of the
role of the gut microbiota in individualised responses to dietary interventions, thus highlighting the
possibility of the use of gut microbial analysis as a method for tailoring dietary advice [27,28].
3.1. Phenotyping of Individuals to Enable Precision Nutrition
A key aspect that will be essential for the development of precision nutrition will be the use of
nutrigenomic approaches to allow phenotyping at the individual level. In recent years the application
of metabolomics has emerged as a powerful tool in the identification of individual responses to drug
therapies [29–31], and the concept of metabotypes has emerged where different metabotypes display
differential responses. A similar concept holds true for nutrition with the identification of metabotypes
that characterise differential responses to nutrition interventions [32,33]. The importance of such
approaches lies in the identification of a biomarker signature that could be used to deliver tailored
dietary advice.
An important area where metabolomics is set to play an important role is the development of
biomarkers that are related to the efficacy of a certain dietary regime.
Currently, prognostic and diagnostic biomarkers are used to assess the efficacy of a diet or
bioactive food compound in the short or longer term. Both types of biomarkers are indicators for
a disorder that has already developed, which is very relevant for a chronic disease like cardiovascular
disease or type 2 diabetes, which have the potential to start developing in the first decade of life [34].
Several biomarkers and criteria have been proposed to validate the influence of food components
on specific physiological functions, such as type 2 diabetes [35] and cardiovascular disease [36].
The application of prognostic and diagnostic biomarkers in human intervention studies, however,
is often not straight forward for at least three reasons. Firstly, our current collection of classic or
new biomarkers is clearly not adequate for explaining how diet or food compounds can decrease
cardiovascular disease risk, especially in relation to pathways involved in inflammation and oxidative
stress. Secondly, although the classical and new biomarkers might be perfectly able to indicate the
risk of cardiovascular disease in patients, or identify modification of risk through pharmacological
intervention, such markers may not always be appropriate for subtle dietary interventions in subjects
that are relatively healthy. Thirdly, the link between diet and chronic diseases is complex and difficult
to unravel. Our diet is made up of many different food compounds and nutrients, and most of these
may uniquely affect risk of developing vascular disease. Only when we address all these issues we
can seriously progress with the measurement of the efficacy of dietary nutrients to benefit health [37].
The development of biomarkers of health is even more challenging. The World Health
Organization (WHO) defined health in 1948 as “a state of complete physical, mental, and social
well-being and not merely the absence of disease or infirmity” [38], and based on this, it has been
proposed that the formulation of health should be the “ability to adapt and to self-manage” [39].
Therefore, the instruments to measure health should not only be those markers we use to assess
the risk of developing chronic diseases, such as blood pressure, plasma lipids, and blood glucose.
Instead, markers to measure health should relate to resilience and the ability to cope with stresses to
the system that prevent disease from happening in the first place [40]. With this in mind, the concept
of the challenge test has emerged where an individual′s response to a meal challenge is monitored
and biomarkers indicative of a healthier response are beginning to emerge [41,42]. The use of such
biomarkers to guide the delivery of personalised nutrition advice has significant opportunity but
needs further proof of concept studies.
A further aspect that is equally important in the delivery of precision nutrition is the development
of tools to assess dietary intake and nutrition status. Diet is a complex, multi-dimensional exposure,
and its assessment requires a multipronged approach which may include high-throughput nutritional
metabolomics complementary to traditional assessment tools such as validated dietary questionnaires
and established nutrient biomarkers. To achieve the goal of precision nutrition, more efforts are needed
to develop, validate, and refine assessment methods that can capture the multidimensional nature of
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diet [43]. Exciting new developments in the area of point-of-care diagnostics promise improved access
to nutritional status assessment, which would be a first step towards tailored interventions. However,
a systematic evaluation of their accuracy, reproducibility, and sensitivity is mostly lacking [44]. With the
application of metabolomics, new biomarkers of dietary intake are emerging [45]. Importantly,
we have recently demonstrated that such biomarkers are capable of determining dietary intake at the
g/day level [46]. Using a well-controlled feeding study we developed calibration curves between the
biomarker urinary level and the actual amount of food consumed (citrus fruit). Using these calibration
curves we were able to determine the citrus fruit intake in a population study using the biomarker
proline betaine. The importance of this lies in the potential use of combinations of biomarkers to
determine the intake of important foods in the diet. Furthermore, combining dietary biomarkers with
the classical approaches has the potential to improve our ability to accurately assess dietary intake.
Indeed, in recent years, research on the development and validation of methods of online recording
of food intake has expanded significantly [47]. However, the accurate monitoring of dietary intake,
especially those based on web-based tools, remains a significant challenge, especially when applying
such tools across countries due to the variety in dietary patterns and available food databases.
In addition to intake, exposure to food components should be taken into account when trying
to link dietary nutrients and patterns to health or disease development. Factors such as gender,
age and host genetic, and epigenetic variations in metabolising enzymes cause major differences in the
actual bioavailability of nutrients between people, as discussed above. More advanced metabolomic
assessment of individuals after the consumption of specific diets, in relation to information obtained
from dietary assessment tools, is expected to provide novel biomarkers for a range of food exposures.
Dried blood spots (DBS) are a promising tool to assess dietary intake and the nutritional status of
certain dietary components in population-based epidemiology studies, because DBS can be collected
by non-phlebotomists in non-clinical settings, and are more easily transported and stored. However,
DBS methods need to be carefully developed and validated against venous methods [48,49]. Overall,
with the development of the latest nutrigenomic technologies, their potential use in the delivery
of precision nutrition grows. While more work is needed in the development of aspects such as
the biomarkers of health, it is also imperative that we commence testing the n-of-1 approach and
demonstrate its utility.
3.2. Nutrigenetics
Lifestyle interventions, including dietary interventions, which alter the health or disease status
against a background of genetic variability, are identified mainly via population-based approaches in
genome-wide association studies (GWAS). For common complex diseases, however, the GWAS-driven
advances in the annotation of our genetic architecture over the past decade have not led to
a concomitant shift in refined treatments. Similarly, attempts to disentangle treatment responders from
non-responders via genetic predictors have not met their anticipated success [50].
Determining whether corresponding changes in diet in turn favourably shift disease risks requires
appropriately designed prospective studies. In recent last decades, hundreds of nutrigenetics studies
have attempted to establish the role of single SNPs in explaining inter-individual variability in response
to diets and nutrients. Whilst important to do, we have learned little in terms of the overall impact on
health. Most nutrigenetics studies are based on associations only–in these cases, a higher response
to a specific dietary factor or nutrient was observed for a particular genotype at a candidate gene
locus. However, genetic association studies often have limited statistical power and also frequently
lack reproducibility. Indeed, most studies are unique and findings have not been confirmed by
others. Thus far only two studies were designed such that subjects were recruited prospectively
based on genotype. One multi-centre double-blind placebo-controlled human intervention study in
312 adults assessed the effects of fish oil supplements on APOE-genotype dependent changes in plasma
triglycerides levels (FINGEN study). The investigators observed that whilst plasma triacylglycerol
concentrations were lowered in the group as a whole, the greatest triacylglycerol-lowering responses
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were evident in men carrying the apolipoprotein E4 (APOE4) variant [51]. A second study investigated
the effect of riboflavin, the cofactor for methylenetetrahydrofolate reductase (MTHFR), on blood
pressure in patients who were homozygous for the 677C→T polymorphism (TT genotype) in the
gene encoding for MTHFR. In this placebo-controlled crossover study, patients with the TT genotype
had higher systolic blood pressure at baseline, and the riboflavin supplementation produced an
overall significant and physiologically relevant decrease in systolic and diastolic blood pressure [52].
Apart from these two studies, no other available studies give conclusive evidence for the role of distinct
single SNPs in the individual response to dietary changes or nutrient status.
It could be argued that single genotypes have generally poor predictive value for health outcomes.
However, in almost all complex diseases and in particular in the non-communicable diseases, a few
tens or even hundreds of genes are involved in a phenotypic trait. Moreover, downstream processes
such as epigenetics, miRNA interference, and other forms of posttranslational alterations of protein
functions will affect the proteome and metabolome, and are thus contributing substantially to the
phenotype. The importance of these effectors is just starting to emerge from large scale cohort studies.
This all shows that the current state of nutrigenetics is currently of limited value for an individual
or the public in guiding healthy nutrition. Therefore, it would be premature to apply our knowledge
in the field of nutrigenetics to personalised diets for specific genotypes [53]. This observation was
confirmed recently in a large proof-of-principle study in a pan-European cohort (www.Food4Me.org)
to establish the effectiveness of an internet-based personalised nutrition approach in improving dietary
behaviours. Participants randomised to the personalised nutrition arms of the intervention study had
an overall increase in the healthy eating index, lower salt intake, and lower intake of red meat based on
general healthy dietary advice and/or knowledge of individual nutrient status. Importantly, including
genotypic information in the development of the personalised nutrition advice did not produce any
additional benefit [25].
4. Conclusions
An increasing number of studies indicate the need to apply precision nutrition approaches to
personalise disease risk and, in parallel, future dietary recommendations. Further developments in this
area will depend on big data analysis and health informatics that can capture molecular and medical
data. Ultimately, the success of precision nutrition approaches will depend on the robust application
of appropriate study designs as the predictive role of biomarkers cannot be definitively ascertained
without randomly assigning subjects to some form of control treatment [54].
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